Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®*
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,…
European Commission approves FYB201/Ranivisio®1 (Ranivisio – Ranibizumab), a biosimilar to Lucentis®2
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (…
Polpharma Biologics announces FDA file acceptance for review of natalizumab, first proposed biosimilar to Tysabri®
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol…
Polpharma Biologics announces EMA acceptance of Marketing Authorization Application for proposed biosimilar natalizumab
Amsterdam, The Netherlands, 14th of July 2022 Polpharma Biologics, an international biotech company dedicated to the development of biosimilars, announced today that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for biosimilar natalizumab, a proposed biosimilar to Tysabri®*. The application is for an intravenous (IV) route of administration, with the […]
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
MHRA’s authorization for BIOEQ’s biosimilar in the United Kingdom.
We are pleased to share last week’s news on the approval of the marketing authorization application of BIOEQ’s Lucent…
Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered into a commercialization agreement for biosimilar Ranibizumab
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the “we…
Bioeq, the Polpharma Biologics Group joint venture company and MS Pharma sign exclusive agreement for Ranibizumab in MENA
Zug, Switzerland – MS Pharma has signed an exclusive licensing and supply agreement with Bioeq AG, Switzerland, the P…
Polpharma Biologics Group announces that the Biologics License Application (BLA) submitted by its joint venture Bioeq for its biosimilar Ranibizumab has been accepted for review by the U.S. Food and Drug Administration (FDA)
Bioeq has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application…
Rapid growth of Polish biotechnology sector leads to demand for foreign expertise, as Polpharma Biologics announces 70 new vacancies
The new roles come on top of significant growth at the company in the last two years, with an additional 300 employee…
Polpharma Biologics Group announces that its joint venture Bioeq has submitted a biologics license application (BLA) for biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has…